Immune checkpoint inhibitors (ICIs) changed management of non-small-cell lung cancer, but resistance usually develops. Today, at ICIs failure, chemotherapy is the treatment of choice, but the chance of immunotherapy rechallenge is appealing. Another challenging issue is whether it is safe to treat HIV-positive patients with ICIs: safety and efficacy of immunotherapy have been marginally considered in this subgroup. We report the case of a non-small-cell lung cancer patient treated by PD-1 inhibitors rechallenge despite his HIV-positivity, achieving good partial response with significant clinical benefit and without toxicities. Our experience underlines that HIV-positive patients can be treated similarly to HIV-negative individuals. HIV-positivity should be considered similar to other comorbidities, and not as a sufficient reason to preclude them the best available treatments.

Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: A case report / Guaitoli, G.; Barbieri, F.; Barbolini, M.; Molinaro, E.; Emidio, K. D.; Borghi, V.; Dominici, M.; Bertolini, F.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 13:4(2021), pp. 277-281. [10.2217/imt-2020-0180]

Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: A case report

Molinaro E.;Borghi V.;Dominici M.;
2021-01-01

Abstract

Immune checkpoint inhibitors (ICIs) changed management of non-small-cell lung cancer, but resistance usually develops. Today, at ICIs failure, chemotherapy is the treatment of choice, but the chance of immunotherapy rechallenge is appealing. Another challenging issue is whether it is safe to treat HIV-positive patients with ICIs: safety and efficacy of immunotherapy have been marginally considered in this subgroup. We report the case of a non-small-cell lung cancer patient treated by PD-1 inhibitors rechallenge despite his HIV-positivity, achieving good partial response with significant clinical benefit and without toxicities. Our experience underlines that HIV-positive patients can be treated similarly to HIV-negative individuals. HIV-positivity should be considered similar to other comorbidities, and not as a sufficient reason to preclude them the best available treatments.
13
4
277
281
Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: A case report / Guaitoli, G.; Barbieri, F.; Barbolini, M.; Molinaro, E.; Emidio, K. D.; Borghi, V.; Dominici, M.; Bertolini, F.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 13:4(2021), pp. 277-281. [10.2217/imt-2020-0180]
Guaitoli, G.; Barbieri, F.; Barbolini, M.; Molinaro, E.; Emidio, K. D.; Borghi, V.; Dominici, M.; Bertolini, F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1239235
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact